IE
KYNB

Israel Englander’s Kyntra Bio KYNB Stock Holding History

Israel Englander’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,675
Closed -$137K – 6003
2025
Q1 		$137K Sell
17,675
-15,549
-47% -$186K ﹤0.01% 5382
2024
Q4 		$440K Sell
33,224
-5,374
-14% -$49.9K ﹤0.01% 4842
2024
Q3 		$385K Sell
38,598
-45,547
-54% -$687K ﹤0.01% 5028
2024
Q2 		$1.88M Buy
84,145
+79,495
+1,710% +$2.46M ﹤0.01% 3587
2024
Q1 		$273K Sell
4,650
-19,646
-81% -$846K ﹤0.01% 5191
2023
Q4 		$538K Sell
24,296
-66,346
-73% -$1M ﹤0.01% 4597
2023
Q3 		$1.96M Sell
90,642
-45,694
-34% -$1.79M ﹤0.01% 3571
2023
Q2 		$9.2M Buy
136,336
+112,419
+470% +$46.5M ﹤0.01% 2105
2023
Q1 		$11.2M Buy
23,917
+16,869
+239% +$8.93M 0.01% 1846
2022
Q4 		$2.82M Buy
7,048
+5,825
+476% +$2.23M ﹤0.01% 3268
2022
Q3 		$398K Sell
1,223
-2,329
-66% -$750K ﹤0.01% 5140
2022
Q2 		$938K Buy
3,552
+3,036
+588% +$776K ﹤0.01% 4419
2022
Q1 		$155K Sell
516
-4,593
-90% -$1.6M ﹤0.01% 5950
2021
Q4 		$1.8M Sell
5,109
-23,583
-82% -$7.34M ﹤0.01% 3874
2021
Q3 		$7.33M Buy
28,692
+28,233
+6,151% +$10M ﹤0.01% 2428
2021
Q2 		$306K Buy
459
+152
+50% +$87.6K ﹤0.01% 5705
2021
Q1 		$266K Sell
307
-1,890
-86% -$2.01M ﹤0.01% 5298
2020
Q4 		$2.04M Buy
2,197
+1,840
+515% +$1.93M ﹤0.01% 3217
2020
Q3 		$367 Sell
357
-6,476
-95% -$6.97M ﹤0.01% 3736
2020
Q2 		$6.92M Buy
6,833
+2,989
+78% +$2.78M 0.01% 1488
2020
Q1 		$3.34M Buy
3,844
+3,625
+1,655% +$3.6M 0.01% 1645
2019
Q4 		$235K Sell
219
-2,091
-91% -$2.13M ﹤0.01% 3794
2019
Q3 		$2.14M Buy
+2,310
New +$2.54M ﹤0.01% 2401
2019
Q2 		– Sell
-6,695
Closed -$9.1M – 4164
2019
Q1 		$9.1M Buy
6,695
+6,467
+2,836% +$8.77M 0.01% 1329
2018
Q4 		$264K Sell
228
-4,036
-95% -$4.54M ﹤0.01% 3276
2018
Q3 		$6.48M Buy
4,264
+3,762
+749% +$5.79M 0.01% 1617
2018
Q2 		$785K Sell
502
-3,528
-88% -$4.6M ﹤0.01% 2962
2018
Q1 		$4.66M Buy
4,030
+3,336
+481% +$4.39M 0.01% 1846
2017
Q4 		$823K Buy
+694
New +$870K ﹤0.01% 2814
2017
Q2 		– Sell
-5,734
Closed -$3.53M – 3574
2017
Q1 		$3.53M Sell
5,734
-11,646
-67% -$7.09M 0.01% 1662
2016
Q4 		$9.3M Buy
17,380
+3,212
+23% +$1.6M 0.02% 968
2016
Q3 		$7.33M Buy
14,168
+5,432
+62% +$2.56M 0.01% 1103
2016
Q2 		$3.58M Buy
+8,736
New +$4M 0.01% 1458
2015
Q4 		– Sell
-5,990
Closed -$3.28M – 3516
2015
Q3 		$3.28M Buy
+5,990
New +$3.63M 0.01% 1595
2015
Q2 		– Sell
-483
Closed -$379K – 3476
2015
Q1 		$379K Sell
483
-296
-38% -$230K ﹤0.01% 2902
2014
Q4 		$532K Buy
+779
New +$501K ﹤0.01% 2937

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Israel Englander's KYNB Position: Q2 2025 in Review

Israel Englander sold out of Kyntra Bio (KYNB) in Q2 2025, closing a stake of 17,675 shares — an estimated $137K sold.

Israel Englander first reported a position in KYNB in Q4 2014 and held it in 36 quarters. The position peaked at $11.2M in Q1 2023. 30 funds tracked by Wall St. Rank hold KYNB as of Q2 2025.

  • Israel Englander reported no remaining Kyntra Bio position as of Q2 2025 after selling out during the quarter.
  • Israel Englander sold 17,675 Kyntra Bio shares in Q2 2025, an estimated $137K.
  • Israel Englander first reported a position in Kyntra Bio in Q4 2014 and held it in 36 quarters.
  • Israel Englander's Kyntra Bio position peaked at $11.2M in Q1 2023.
  • 30 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.